Nebulized Amphotericin B for Lung Transplant Prophylaxis
For lung transplant recipients, administer nebulized liposomal amphotericin B (L-AMB) at 25 mg three times weekly initially, transitioning to once weekly from months 2-6, then once every two weeks from month 6 onward, continuing indefinitely.
Formulation Selection
Use liposomal amphotericin B (L-AMB) rather than amphotericin B deoxycholate for nebulization. L-AMB demonstrates superior tolerability with significantly fewer respiratory adverse events (6.9% vs 30.3%) while maintaining comparable efficacy and lower daily costs 1, 2. Amphotericin B lipid complex (ABLC) at 50 mg is an acceptable alternative with similar efficacy 1.
Dosing and Schedule
The guideline-recommended regimen follows a stepwise de-escalation 1:
- Initial phase (until bronchial suture resolution): 25 mg L-AMB three times weekly
- Months 2-6: Once weekly
- Month 6 onward: Once every two weeks
- Duration: Indefinite (lifelong prophylaxis)
Alternative dosing with ABLC uses 50 mg on the same schedule 1. Some centers successfully use twice-daily dosing, though three-times-daily administration showed lower infection rates (4% vs 17%) in comparative studies 3.
Clinical Efficacy
This prolonged prophylaxis strategy achieves excellent outcomes. In a large cohort of 802 lung transplant recipients receiving lifelong nebulized L-AMB, the breakthrough mold infection rate was only 8.7% at one year and 11.7% over median 2.56-year follow-up 4. Prolonged courses (>3 months) significantly outperform shorter durations, with 1-year invasive fungal disease rates of 12.6% versus 28.0% for medium courses (2 weeks-3 months) and 50.9% for short courses (<2 weeks) 5.
Safety and Tolerability
Bronchospasm is the primary adverse effect to monitor 1. However, discontinuation rates due to adverse events remain remarkably low at only 2.2% with long-term use 4. The medication achieves therapeutic concentrations in epithelial lining fluid (7.20 μg/mL at 4 hours, persisting above MIC for Aspergillus up to 168 hours) with minimal systemic absorption (plasma levels <0.08 μg/mL) 6.
Common but manageable side effects include coughing and mild respiratory irritation. Pre-treatment with bronchodilators can mitigate bronchospasm risk 7.
Administration Technique
- Reconstitute according to manufacturer guidelines for the specific formulation
- Use appropriate nebulizer equipment validated for amphotericin delivery
- Administer via standard jet nebulizer or vibrating mesh nebulizer
- No specific pre-medication required unless bronchospasm history exists
- Monitor for cough, wheezing, or dyspnea during initial doses
Monitoring Parameters
- Respiratory symptoms: Assess for cough, bronchospasm, dyspnea with each dose initially
- Fungal surveillance: Regular respiratory cultures per transplant protocol
- Liver function: Not required for nebulized formulation (unlike systemic voriconazole which causes hepatotoxicity in 60% of patients) 1
- No therapeutic drug monitoring needed for nebulized amphotericin
Key Clinical Considerations
Risk factors for breakthrough infection despite prophylaxis include bronchial stenosis, bronchial stent placement, and single lung transplant 4. These patients warrant heightened surveillance but should continue prophylaxis as breakthrough infections correlate with significantly increased mortality (adjusted HR 14.07) 4.
The emergence of amphotericin B-nonsusceptible molds during prolonged prophylaxis does not increase mortality risk, supporting the safety of indefinite use 4.
Combination therapy: Some centers add systemic azoles (voriconazole 200 mg twice daily or itraconazole) for very high-risk patients, though this increases hepatotoxicity and drug interaction monitoring burden 1. Nebulized amphotericin alone provides adequate prophylaxis for most recipients.
Practical Implementation
The indefinite duration recommendation reflects that lung transplant recipients maintain lifelong immunosuppression and fungal infection risk. The de-escalating schedule balances efficacy with patient burden and cost. Excellent tolerability (99.5% of patients receive at least one dose, 90.2% complete recommended courses) supports this long-term approach 8.
Cost considerations: L-AMB costs approximately 1792 Japanese yen daily versus 3609 yen for deoxycholate formulation, making L-AMB both safer and more economical 2.